Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer (Q34156513)

31 July 2017

title

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer (English)

1 reference

31 July 2017

1 reference

Elisa de Stanchina

0 references

Kwok Kin Wong

object named as

Kwok-Kin Wong

1 reference

31 July 2017

Marc Ladanyi

1 reference

31 July 2017

Qingguo Wang

0 references

Gavin M Wright

0 references

William Pao

1 reference

31 July 2017

Christine M Lovly

1 reference

31 July 2017

Nerina T McDonald

1 reference

31 July 2017

Heidi Chen

1 reference

31 July 2017

Sandra Ortiz-Cuaran

1 reference

31 July 2017

Lukas C Heukamp

1 reference

31 July 2017

Yingjun Yan

1 reference

31 July 2017

Alexandra Florin

1 reference

31 July 2017

Luka Ozretić

1 reference

31 July 2017

Ronglai Shen

1 reference

31 July 2017

Sascha Ansén

1 reference

31 July 2017

Sven Perner

1 reference

31 July 2017

Monica Red-Brewer

1 reference

31 July 2017

Zhongming Zhao

1 reference

31 July 2017

Masyar Gardizi

1 reference

31 July 2017

Xi Chen

1 reference

31 July 2017

Diana Lim

1 reference

31 July 2017

Lu Wang

1 reference

31 July 2017

Zhao Chen

1 reference

31 July 2017

Pengcheng Lu

1 reference

31 July 2017

Paul K Paik

1 reference

31 July 2017

Hailing Jin

1 reference

31 July 2017

Reinhard Buettner

1 reference

31 July 2017

Michael Brockmann

1 reference

31 July 2017

Marc Bos

1 reference

31 July 2017

Jürgen Wolf

1 reference

31 July 2017

Benjamin Solomon

1 reference

31 July 2017

Prudence A Russell

1 reference

31 July 2017

Toni-Maree Rogers

1 reference

31 July 2017

Yoshiyuki Suehara

1 reference

31 July 2017

Rudy Tieu

1 reference

31 July 2017

David H Johnson

1 reference

31 July 2017

Leora Horn

1 reference

31 July 2017

Roman K Thomas

1 reference

31 July 2017

language of work or name

English

0 references

publication date

31 August 2014

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

1027-1034

1 reference

describes a project that uses

31 July 2017

limma

1 reference

22 June 2022

https://europepmc.org/article/PMC/4159407

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Genome sequencing identifies a basis for everolimus sensitivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

The Sequence Alignment/Map format and SAMtools

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Fast and accurate short read alignment with Burrows-Wheeler transform

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

beadarray: R classes and methods for Illumina bead-based data.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4159407

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNM.3667

Insulin Receptor Substrate Regulation of Phosphoinositide 3-Kinase

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNM.3667

21 January 2018

Identifiers

DOI

10.1038/NM.3667

1 reference

31 July 2017

1 reference

31 July 2017

1 reference